These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. New treatment options for HIV salvage patients: an overview of second generation PIs, NNRTIs, integrase inhibitors and CCR5 antagonists. Hughes A; Barber T; Nelson M J Infect; 2008 Jul; 57(1):1-10. PubMed ID: 18556070 [TBL] [Abstract][Full Text] [Related]
3. HIV-1 antiretroviral drug therapy. Arts EJ; Hazuda DJ Cold Spring Harb Perspect Med; 2012 Apr; 2(4):a007161. PubMed ID: 22474613 [TBL] [Abstract][Full Text] [Related]
4. Comparative efficacy and safety of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: a systematic review and network meta-analysis. Snedecor SJ; Radford M; Kratochvil D; Grove R; Punekar YS BMC Infect Dis; 2019 May; 19(1):484. PubMed ID: 31146698 [TBL] [Abstract][Full Text] [Related]
5. New developments in anti-HIV chemotherapy. De Clercq E Biochim Biophys Acta; 2002 Jul; 1587(2-3):258-75. PubMed ID: 12084468 [TBL] [Abstract][Full Text] [Related]
6. New anti-HIV agents and targets. De Clercq E Med Res Rev; 2002 Nov; 22(6):531-65. PubMed ID: 12369088 [TBL] [Abstract][Full Text] [Related]
7. The development of anti-HIV-1 drugs. Lu XF; Chen ZW Yao Xue Xue Bao; 2010 Feb; 45(2):165-76. PubMed ID: 21348415 [TBL] [Abstract][Full Text] [Related]
8. The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. De Clercq E Antiviral Res; 1998 Jun; 38(3):153-79. PubMed ID: 9754886 [TBL] [Abstract][Full Text] [Related]
12. Delavirdine: a review of its use in HIV infection. Scott LJ; Perry CM Drugs; 2000 Dec; 60(6):1411-44. PubMed ID: 11152019 [TBL] [Abstract][Full Text] [Related]
13. Newer antiretroviral agents and how to use them. Kim HH; Daar ES Curr HIV/AIDS Rep; 2009 May; 6(2):55-62. PubMed ID: 19358775 [TBL] [Abstract][Full Text] [Related]
14. Phenotypic analysis of the sensitivity of HIV-1 to inhibitors of the reverse transcriptase, protease, and integrase using a self-inactivating virus vector system. Jármy G; Heinkelein M; Weissbrich B; Jassoy C; Rethwilm A J Med Virol; 2001 Jul; 64(3):223-31. PubMed ID: 11424108 [TBL] [Abstract][Full Text] [Related]
15. Susceptibility of Human Endogenous Retrovirus Type K to Reverse Transcriptase Inhibitors. Contreras-Galindo R; Dube D; Fujinaga K; Kaplan MH; Markovitz DM J Virol; 2017 Dec; 91(23):. PubMed ID: 28931682 [TBL] [Abstract][Full Text] [Related]
19. HIV-1 genotype after interruption of non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy and virological response after resumption of the same regimen. Sungkanuparph S; Kiertiburanakul S; Apisarnthanarak A; Malathum K; Sathapatayavongs B Int J STD AIDS; 2007 Dec; 18(12):832-4. PubMed ID: 18073016 [TBL] [Abstract][Full Text] [Related]